Immune booster after transplant aims to stop leukemia return
NCT ID NCT03300492
First seen Jan 06, 2026 · Last updated Jun 04, 2026 · Updated 20 times
Summary
This study is for adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who have had a stem cell transplant from a half-matched donor. After the transplant, participants receive extra immune cells called natural killer (NK) cells from the same donor to try to prevent the cancer from coming back. The main goal is to see if this approach is safe and feasible, and to monitor for side effects like graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Basel
RECRUITINGBasel, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.